Irvine Scientific’s new product range includes chemically-defined, serum-free media, to increase productivity of viral vectors and recombinant proteins in suspension cultures.
Irvine Scientific, a company specializing in the optimization and manufacture of cell culture media has launched a new system, BalanCD HEK293 System, which has a versatile series of chemically-defined media, designed to increase productivity and deliver high yields of viral vectors and recombinant proteins.
According to Irvine Scientific, the BalanCD HEK293 System is fully scalable, and supports small to industrial scale batch sizes. The system uses human embryonic kidney (HEK293) cells and can support applications including viral vector production for gene therapy, transient gene expression, and recombinant protein production in suspension-adapted HEK293 cells.
BalanCD HEK293 growth and feed media have been designed to be chemically-defined and free of animal components, so that it saves time and cost in downstream processing, as well as meets regulatory requirements. The BalanCD HEK293 bi-functional medium supports both growth and transfection in multiple 293 cell lines, eliminating the need to change media before and after transfection. Complementing it is the BalanCD HEK293 Feed, which has been designed to support high-density cell growth to maximize production of recombinant proteins.
Anti-clumping supplement further increases productivity by preventing the natural tendency of HEK293 to aggregate, thereby, improving growth. Anti-clumping supplement is also animal-component-free and enzyme-free.
All products are manufactured in state-of-the-art cGMP facilities using strict raw material controls. Drug master files have been submitted to FDA.
Source: Irvine Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
2 Commerce Drive
Cranbury, NJ 08512